Eisai US logo

Eisai US

At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US. Comments and posts by users on this site are not created or controlled by Eisai Inc. and Eisai is not responsible for such content.

Free account • No credit card • 5 profiles/day

Pharmaceutical Manufacturing 2,746 Employees Found United States Founded 1995 1930 Similar Companies
2,746 Employees Found
90% Email Coverage
$6.6B Est Revenue
+3% YoY Headcount Growth
2 Office HQ
1930 Similar Companies
Sep '26 Last Verified

Eisai US – Company Information

Pharmaceutical Manufacturing
Founded 1995
1,001-5,000 employees View all
200 Metro Blvd., Nutley, NJ, 07110, US
WordPress React Office 365 Mail Microsoft Azure Slack New Relic Vue Angular JS Amazon S3 Workday DocuSign Okta
Aug 2026
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection

The FDA approved a new subcutaneous injection option for Biogen and Eisai's Alzheimer's treatment.

May 2026
Eisai's slow push toward blockbuster Leqembi sales gains steam

Eisai projects strong sales growth for its Alzheimer's disease treatment following a doubled performance in the previous fiscal year.

Feb 2026
Fosun Pharma unit licenses lung cancer drug to Eisai

Eisai entered a major US$1.55 billion licensing deal to add a home-grown cancer drug to its portfolio.

Jan 2026
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement

Eisai expanded its oncology footprint through an exclusive partnership for taletrectinib outside major regions.

Find Eisai US contacts

Decision Makers by Function

Scott Steuart

Scott Steuart

VP

Vice President, Market Access, Eisai • Champion • 6 years

View
Sarah Ross

Sarah Ross

Director

Area Business Leader • Influencer • 3 years

View
Marcus Taylor -

Marcus Taylor -

Head

Area Business Leader - Oncology • Champion • 5 years

View
Seth Dunn

Seth Dunn

Director

Director, Procurement Operations & P2P • Influencer • 5 years

View
Supriya Shoroff

Supriya Shoroff

Director

Senior Director, TMF Operations • Influencer • 2 years

View
Sarah B Shpetner

Sarah B Shpetner

Director

Director, Meetings & Conventions • Influencer • 5 years

View
Erica Andreozzi

Erica Andreozzi

Director

Associate Director, Clinical Development • Influencer • 5 years

View
Bobby White

Bobby White

Director

Director Medicaid Market Access • Influencer • 7 years

View
Carol Rockett

Carol Rockett

Director

Senior Director Medical Affairs • Influencer • 3 years

View

Tonya M Gilbert

Director

Director, External Innovation • Influencer • 7 months

View
Venkat Mutavi

Venkat Mutavi

Director

Director, Global Analytics and Forecasting • Influencer • 1 year

View

Ravi Dangeti

Director

Director, Statistical Programming • Influencer • 2 years

View

Frequently asked questions about Eisai US

What is Eisai US email format?

The widely used Eisai US email format is {first}_{last} (e.g. john_smith@us.eisai.com) with 73.6% adoption across the company.

What is Eisai US customer service number?

To contact Eisai US customer service number in your country click here to find.

Who are the decision makers in Eisai US?

The decision makers in Eisai US are Brian Harraka, Margaret Moline, Tianle Hu, etc. Click to Find Eisai US decision makers emails.